Indeed, commonly used IBD therapies, both biologic and non-biologic, do not appear to significantly affect ACE2 or TMPRSS2 expression patterns in uninflamed intestinal tissue [62,78], although one study reported downregulation of colonic ACE2 expression in IBD patients who responded to anti-TNFα therapy [76]. Here, ACE2 is linked to inflammatory bowel disease.